Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    CA220-007
Show Display Options
Rank Status Study
1 Completed Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
Condition: Melanoma
Interventions: Biological: BMS-982470 (recombinant interleukin-21);   Biological: Ipilimumab

Study has passed its completion date and status has not been verified in more than two years.